Results 181 to 190 of about 5,903 (227)

Fluoropyrimidines as radiation sensitizers

Seminars in Radiation Oncology, 1993
The fluorop'yTimidines 5-fluorouracil (5-FU) and 5-fluoro-2'-deoxyuridine (FdUrd) are the most widely used radiation sensitizers in clinical practice. As is rex4ewed elsewhere in this issue, a large number of retrospective and prospective studies have suggested that the combination of 5-FU and radiation is efficacious in the treatment of ...
Theodore S. Lawrence, Jonathan Maybaum
openaire   +1 more source

Review of the Fluoropyrimidine Antidote Uridine Triacetate

British Journal of Clinical Pharmacology
not-yet-known not-yet-known not-yet-known unknown In 2015, the United States Food and Drug Administration (FDA) approved uridine triacetate to treat overdose and severe toxicity of the fluoropyrimidine chemotherapy agents 5-fluorouracil (5-FU) and its oral prodrug capecitabine.
Jack T. Thompson, David M. Wood, Paul I. Dargan   +2 more
openaire   +2 more sources

Synthesis of 5-fluoropyrimidines

Journal of the Chemical Society, Perkin Transactions 1, 1974
Fluorination with trifluorofluoro-oxymethane is a convenient general procedure for the synthesis of 5-fluoropyrimidines, including 5-fluorobarbituric acids.
Derek H. R. Barton, William A. Bubb, Robert H. Hesse, Maurice M. Pechet   +3 more
openaire   +1 more source

Fluoropyrimidine cancer chronotherapy

1994
In 1972, a paper appeared in Science which reported that the arrangement within a given day of 3-hourly doses of Cytosine arabinoside (Ara-C) had a profound effect on the survival rate of mice inoculated with L-1210 leukemia cells [1]. This study was built on extensive prior work demonstrating that all Ara-C toxicities are markedly dependent on the ...
W. J. M. Hrushesky, F. O. Cope
openaire   +1 more source

Fluoropyrimidines as Antifolate Drugs

1999
5 Fluorouracil (5FU) is a rationally designed antineoplastic agent (1,2) with distinct antifolate and antipyrimidine properties. 5FU is usually given in combination with other agents for the treatment of various types of cancer (3–11) such as cancers of the gas-trointestinal tract, breast cancer, and head and neck cancer.
G. J. Peters, C. H. Köhne
openaire   +1 more source

Advances and Challenges in Fluoropyrimidine Pharmacogenomics and Pharmacogenetics

Pharmacogenomics, 2005
In cancer pharmacogenetics (the study of how variability in a single or set of known genes influences drug response) and pharmacogenomics (the study of variability on a genome-wide scale), one of the most important fields of research focuses on the fluoropyrimdines (FPs) and, in particular, 5-fluorouracil (5-FU).
Richie, Soong, Robert B, Diasio
openaire   +2 more sources

Fluoropyrimidines as Radiation Sensitizers

2003
Radiation sensitization with concurrent chemotherapy with an aim to improve radioresponse has long been a focus of investigation. As a result of these efforts, the concomitant use of cytostatic drugs and radiation has become the standard approach for many tumors including head and neck, rectal, anal, esophageal, pancreatic, and gastric cancers.
Muhammad Wasif Saif, Robert B. Diasio
openaire   +1 more source

Developments in fluoropyrimidine therapy for gastrointestinal cancer

Current Opinion in Oncology, 1999
The combination of 5-fluorouracil and leucovorin is the standard treatment in metastatic colorectal cancer and in Dukes' C colon cancer. There is, however, no agreement on the method for administration in metastatic colorectal cancer. Several new studies published in 1998 suggest that infusional 5-fluorouracil gives a higher response rate and better ...
E, Van Cutsem, M, Peeters
openaire   +2 more sources

Mechanisms of resistance to fluoropyrimidines.

Seminars in oncology, 1992
The fluoropyrimidines fluorouracil (5-FU) and 5-fluoro-2'-deoxyuridine (FdUrd) have shown activity in a variety of malignancies. Nevertheless, even in initially responsive tumors, the development of resistance is a frequent problem. To understand the biochemical basis for acquired resistance, two pairs of cell lines were investigated.
Z G, Zhang, A, Harstrick, Y M, Rustum
openaire   +1 more source

[Pharmacokinetics of fluoropyrimidines].

Gan to kagaku ryoho. Cancer & chemotherapy, 1984
Pharmacokinetic behaviors of 5-FU and masked fluoropyrimidines were reviewed. Anabolic and catabolic pathways of 5-FU Pharmacokinetics of 5-FU-blood level, absorption, drug interaction Tegafur (FT)-blood level, absorption, activation to 5-FU by P-450 UFT-high 5-FU level in tissues, especially in tumor tissues, by inhibiting the catabolism of 5-FU from ...
openaire   +1 more source